Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical News News 13 August 2025 - 12 November 2025

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

Published: November 12, 2025 Summary: WeightWatchers says it will sell Wegovy in a pill once launched WeightWatchers (WW) plans to carry Novo Nordisk’s oral Wegovy, pending U.S. approval, leaning into consumer preference for pills over injections and differentiating from rivals pushing cheaper copycat products. The move follows the company’s bankruptcy exit and dovetails with a broader U.S. pricing framework announced last week that targets lower monthly costs for GLP‑1 therapies. Reuters Why it matters: Convenience could further expand GLP‑1 adoption. The White House’s fact sheet outlines headline pricing—$150/month for starter doses of weight‑loss pills through TrumpRx if approved, and $245/month
12 November 2025
·
Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS) of 16.5 months vs. 9.2 months for sunitinib alone (HR=0.50; 95% CI 0.39–0.65; p<0.0001) and a 46% objective response rate vs. 26% on sunitinib monotherapy (p<0.0001). GlobeNewswire “It is a historic day for Cogent Biosciences and the GIST patient community,” CEO Andrew Robbins said, adding that the bezuclastinib combination “is poised to become the new standard of care” in second‑line
10 November 2025
··
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Stock Performance & Recent Market Reaction Intensity Therapeutics shares were flat-to-down during Oct. 2025 until the news, trading around $0.27 on Oct. 29ts2.tech. On Oct. 30 (Thursday), publication of its trial in Lancet sent the stock parabolic: intraday it soared nearly 395%, closing at $1.32benzinga.com. In after-hours trading, the stock gave up much of the gain and traded around $0.90 by the end of Thursdaybenzinga.com. (Benzinga reported a 31.9% after-hours declinebenzinga.com.) A massive volume surge accompanied the move – hundreds of millions of shares changed hands (compared to ~5 million normally)ts2.tech. Despite this spike, INTS remains a micro-cap; even at
31 October 2025
·
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis (ATTR)
8 October 2025
··
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

QURE Stock Update and Analysis as of September 24, 2025 Latest News and Catalysts (September 2025) Historic Huntington’s Results: On September 24, 2025, uniQure revealed landmark Phase I/II trial results for its Huntington’s disease gene therapy AMT-130. In patients treated with a one-time injection of AMT-130, disease progression was significantly slowed – by about 75% over three years for those on the high dose reuters.com. Treated patients maintained far more of their motor and cognitive function compared to the expected decline in Huntington’s, which is an invariably progressive and fatal neurodegenerative disorder reuters.com reuters.com. Crucially, there are currently no approved drugs that slow Huntington’s disease, so these results
24 September 2025
··
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

For the period August 16–17, 2025, the biotech, pharma, medical, and health sectors saw a range of significant developments worldwide. Below is a comprehensive roundup of top stories categorized by theme, complete with expert insights and source links: Clinical Trial Results & Study Readouts Drug & Device Approvals Mergers, Acquisitions & Partnerships Public Health Alerts Research & Medical Breakthroughs Healthcare Policy & Industry Trends Each news item above includes direct source references for verification. This roundup spans clinical trial outcomes, drug approvals, industry deals, public health alerts, research breakthroughs, and policy updates from around the globe during August 16–17, 2025,
17 August 2025
1 2 3

Stock Market Today

Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

7 February 2026
Cadence Bank shares have been delisted following Huntington Bancshares’ takeover, with each Cadence share converted into 2.475 Huntington shares. Huntington closed Friday at $19.27 and named Senthil Kumar as chief risk officer ahead of new regulatory requirements. The merger leaves Cadence as a brand under Huntington, with customer account conversions planned for mid-2026. Huntington executives will address investors at a UBS conference on Tuesday.
NIO stock jumps on profit alert, with Monday’s open in focus

NIO stock jumps on profit alert, with Monday’s open in focus

7 February 2026
NIO shares jumped 7.23% to $5.04 Friday after the company forecast a swing to adjusted operating profit of up to 1.2 billion yuan for the fourth quarter. Trading volume reached 90.8 million shares, far above average. Nio’s deliveries rose 72% to 124,807 vehicles in the quarter. The company said results are preliminary and unaudited, with final figures due in March.
Snap stock price bounces to $5.22 after upgrades — what traders watch next week

Snap stock price bounces to $5.22 after upgrades — what traders watch next week

7 February 2026
Snap Inc. shares closed up 2% at $5.22 Friday after a volatile week, with 94 million shares traded. The company forecast Q1 revenue below analyst expectations, despite a fourth-quarter beat and a 28% rise in active advertisers. Daily active users fell by 3 million to 474 million. Analysts remain divided, with some upgrading and others trimming price targets.
Bradesco stock drops on 2026 guidance — what BBDC4 investors watch next week

Bradesco stock drops on 2026 guidance — what BBDC4 investors watch next week

7 February 2026
Bradesco’s preferred shares fell 2.55% to 20.61 reais Friday after the bank issued 2026 guidance pointing to slower growth in some areas. Fourth-quarter recurring net income rose 20.6% to 6.5 billion reais, with 2025 ROAE at 15.2%. The Ibovespa closed up 0.45%. Bradesco ADRs ended down 0.5% at $3.98 in New York.
Go toTop